image: SU2C logo
Credit: SU2C
LOS ANGELES – March 10, 2025 – Stand Up To Cancer® (SU2C) today announced changes to its Scientific Advisory Committee (SAC), which is composed of cancer research leaders from academic, government, industry and advocacy fields. The SAC oversees SU2C’s scientific research in collaboration with SU2C’s president and CEO Julian Adams, Ph.D.
The new SAC members are:
- Scott A. Armstrong, M.D., Ph.D., SVP for drug discovery and chief research strategy officer at Dana-Farber Cancer Institute and David G. Nathan professor of pediatrics at Harvard Medical School
- Suzanne Dahlberg, Ph.D., associate professor of pediatrics at Harvard Medical School and Boston Children’s Hospital
- Tomas J. Philipson, Ph.D., Daniel Levin professor of public policy emeritus at the University of Chicago
“SU2C is poised to invest in bold science that will harness the latest technologies to greatly reduce cancer deaths in the coming years and I know that our newest SAC members – alongside the entire committee – will be critical partners as this research unfolds,” said Adams. “I’m looking forward to working with Drs. Armstrong, Dahlberg and Philipson and am excited about the expertise they bring to the table in the critical areas of pediatric oncology, biostatistics and healthcare economics.”
Armstrong’s major career focus has been on understanding the biology of pediatric cancers and developing new approaches for treating children with cancer. Specializing in biostatistics, Dahlberg’s work combines designing innovative research studies and tackling statistical issues to improve how medical research is conducted and reported. Philipson’s research focuses on health economics, including the economic aspects of healthcare markets such as personalized medicine, healthcare pricing and policy analysis. The addition of these new SAC members will enhance the diversity of expertise and perspectives while complementing and expanding the committee’s capacity to advise on new SU2C research opportunities.
SU2C’s SAC sets direction for research initiatives, reviews proposals for new grant awards, and conducts rigorous oversight of all active grants in the SU2C research portfolio. The SAC is led by chair William G. Nelson, M.D., Ph.D. at Johns Hopkins Kimmel Cancer Center, and vice chairs John D. Carpten, Ph.D., at City of Hope and Arnold J. Levine, Ph.D., at the Institute for Advanced Study and Cancer Institute of New Jersey.
# # #
Media Contacts:
Mirabai Vogt-James
Stand Up To Cancer
About Stand Up To Cancer
Stand Up To Cancer® (SU2C) raises awareness and funds research to detect and treat cancers with the aspiration to cure all patients. SU2C is a 501(c)(3) charitable organization and was initially launched as a division of the Entertainment Industry Foundation. Established in 2008 by media and entertainment leaders, SU2C utilizes these communities’ resources to engage the public in supporting a new, collaborative model of cancer research, to increase awareness about cancer prevention, and to highlight progress being made in the fight against the disease. As of April 2024, more than 3,100 scientists representing more than 210 institutions are involved in SU2C-funded research projects.
As SU2C’s scientific partner, the American Association for Cancer Research (AACR) and a Scientific Advisory Committee, led by William G. Nelson, M.D., Ph.D., conduct rigorous competitive review processes to identify the best research proposals to recommend for funding, oversee grants administration, and provide expert review of research progress.
Current members of the SU2C Founders and Advisors Committee (FAC) include Katie Couric, Sherry Lansing, Kathleen Lobb, Lisa Paulsen, Rusty Robertson, Sue Schwartz, Pamela Oas Williams, and Ellen Ziffren. The late Laura Ziskin and the late Noreen Fraser are also co-founders. Julian Adams, Ph.D., serves as SU2C’s president and CEO.
For more information visit StandUpToCancer.org, Instagram, TikTok, X, Facebook, and YouTube.